ANGPTL4 and focal segmental glomerulosclerosis: Studies have shown that intravenous administration of recombinant mutant human ANGPTL4, which modifies key interaction sites with LPL, significantly reduces proteinuria in FSGS-afflicted animals without altering plasma TG levels (Clement et al., 2014; Del Nogal-Avila et al., 2016).